Abstract
The nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase, NOX) enzyme family catalyzes the production of reactive oxygen species (ROS). ROS have functional roles in cell cycling and signal transduction but their excessive production results in oxidative stress which is believed to have pathological consequences. Oxidative stress in the intestinal tract is considered a major factor contributing to the pathogenesis and progression of inflammatory bowel disease (IBD), as recent data suggest a positive correlation between upregulated NOX and gastrointestinal inflammation. Moreover, expression of certain NOX gene variants has been shown to affect the susceptibility of an individual to develop IBD. As current treatments for IBD are not entirely effective, the pharmacological inhibition of NOX is an unexplored avenue that could provide a potential therapeutic target for the treatment of this disease.
Keywords: Inflammatory bowel disease (IBD), nicotinamide adenine dinucleotide phosphate oxidase (NADPH), nitric oxide (NO), reactive oxygen species (ROS).
Current Medicinal Chemistry
Title:NADPH Oxidases and Inflammatory Bowel Disease
Volume: 22 Issue: 17
Author(s): Giang Lam, Vasso Apostolopoulos, Anthony Zulli and Kulmira Nurgali
Affiliation:
Keywords: Inflammatory bowel disease (IBD), nicotinamide adenine dinucleotide phosphate oxidase (NADPH), nitric oxide (NO), reactive oxygen species (ROS).
Abstract: The nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase, NOX) enzyme family catalyzes the production of reactive oxygen species (ROS). ROS have functional roles in cell cycling and signal transduction but their excessive production results in oxidative stress which is believed to have pathological consequences. Oxidative stress in the intestinal tract is considered a major factor contributing to the pathogenesis and progression of inflammatory bowel disease (IBD), as recent data suggest a positive correlation between upregulated NOX and gastrointestinal inflammation. Moreover, expression of certain NOX gene variants has been shown to affect the susceptibility of an individual to develop IBD. As current treatments for IBD are not entirely effective, the pharmacological inhibition of NOX is an unexplored avenue that could provide a potential therapeutic target for the treatment of this disease.
Export Options
About this article
Cite this article as:
Lam Giang, Apostolopoulos Vasso, Zulli Anthony and Nurgali Kulmira, NADPH Oxidases and Inflammatory Bowel Disease, Current Medicinal Chemistry 2015; 22 (17) . https://dx.doi.org/10.2174/0929867322666150416095114
DOI https://dx.doi.org/10.2174/0929867322666150416095114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Lack of Association between miR-605 rs2043556 Polymorphism and Overall Cancer Risk: A Meta-analysis of Case-control Studies
MicroRNA Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Repeated Transarterial Chemoembolization with Degradable Starch Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study
Current Medical Imaging Current Approaches for in vitro Drug Release Study of Long Acting Parenteral Formulations
Current Drug Delivery Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Meloxicam-loaded Phospholipid/solutol® HS15 Based Mixed Nanomicelles: Preparation, Characterization, and in vitro Antioxidant Activity
Pharmaceutical Nanotechnology Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy
Current Medicinal Chemistry Recurrent Rearrangements in Prostate Cancer: Causes and Therapeutic Potential
Current Drug Targets β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design